Evidence mounts for a role of the kidney in lipoprotein(a) catabolism  by Albers, J.J. et al.
Kidney International (2007) 71       961
commentar y
distinct congenital and acquired renal diseases. 
J Clin Invest 2003; 111: 707–716.
18. Bdolah Y, Palomaki GE, Yaron Y et al. Circulating 
angiogenic proteins in trisomy 13. Am J Obstet 
Gynecol 2006; 194: 239–245.
19. Nevo O, Soleymanlou N, Wu Y et al. Increased 
expression of sFlt-1 in in vivo and in vitro models 
of human placental hypoxia is mediated by HIF-1. 
Am J Physiol Regul Integr Comp Physiol 2006; 291: 
R1085–R1093.
20. Wolf M, Shah A, Lam C et al. Circulating levels of 
the antiangiogenic marker sFLT-1 are increased 
in first versus second pregnancies. Am J Obstet 
Gynecol 2005; 193: 16–22.
21. Powers RW, Roberts JM, Cooper KM et al. 
Maternal serum soluble fms-like tyrosine kinase 
1 concentrations are not increased in early 
pregnancy and decrease more slowly postpartum 
in women who develop preeclampsia. Am J Obstet 
Gynecol 2005; 193: 185–191.
22. Glusker P, Recht L, Lane B. Reversible posterior 
leukoencephalopathy syndrome and 
bevacizumab. N Engl J Med 2006; 354: 980–982.
23. Hinchey J, Chaves C, Appignani B et al. A 
reversible posterior leukoencephalopathy 
syndrome. N Engl J Med 1996; 334: 494–500.
24. Yang JC, Haworth L, Sherry RM et al. A randomized 
trial of bevacizumab, an anti-vascular endothelial 
growth factor antibody, for metastatic renal 
cancer. N Engl J Med 2003; 349: 427–434.
25. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long 
term mortality of mothers and fathers after pre-
eclampsia: population based cohort study. BMJ 
2001; 323: 1213–1217.
26. Vatten LJ, Romundstad PR, Trichopoulos D, 
Skjaerven R. Pre-eclampsia in pregnancy and 
subsequent risk for breast cancer. Br J Cancer 
2002; 87: 971–973.
27. Bujold E, Romero R, Chaiworapongsa T et al. 
Evidence supporting that the excess of the 
sVEGFR-1 concentration in maternal plasma in 
preeclampsia has a uterine origin. J Matern Fetal 
Neonatal Med 2005; 18: 9–16.
28. Rajakumar A, Michael HM, Rajakumar PA et 
al. Extra-placental expression of vascular 
endothelial growth factor receptor-1, (Flt-1) 
and soluble Flt-1 (sFlt-1), by peripheral blood 
mononuclear cells (PBMCs) in normotensive and 
preeclamptic pregnant women. Placenta 2005; 
26: 563–573.
29. Zhou Y, McMaster M, Woo K et al. Vascular 
endothelial growth factor ligands and receptors 
that regulate human cytotrophoblast survival 
are dysregulated in severe preeclampsia and 
hemolysis, elevated liver enzymes, and low 
platelets syndrome. Am J Pathol 2002; 160: 
1405–1423.
30. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in 
preeclampsia: the “chicken-and-egg” question. 
Endocrinology 2004; 145: 4835–4837.
31. Nagamatsu T, Fujii T, Kusumi M et al. 
Cytotrophoblasts up-regulate soluble fms-like 
tyrosine kinase-1 expression under reduced 
oxygen: an implication for the placental vascular 
development and the pathophysiology of 
preeclampsia. Endocrinology 2004; 145: 4838–
4845.
32. Makris A, Thornton C, Thompson J et al. 
Uteroplacental ischemia results in proteinuric 
hypertension and elevated sFLT-1. Kidney Int 
2007; 71: 977–984.
33. Podjarny E, Losonczy G, Baylis C. Animal models of 
preeclampsia. Semin Nephrol 2004; 24: 596–606.
34. Venkatesha S, Toporsian M, Lam C et al. Soluble 
endoglin contributes to the pathogenesis of 
preeclampsia. Nat Med 2006; 12: 642–649.
see original article on page 1036
Evidence mounts for a role of the 
kidney in lipoprotein(a) catabolism
JJ Albers1, ML Koschinsky2 and SM Marcovina1
Numerous studies have suggested a role of the kidney in lipoprotein(a) 
(Lp(a)) catabolism, but direct evidence is still lacking. Frischmann et al. 
demonstrate that the marked elevation of Lp(a) observed in hemodialysis 
patients results from a decrease in Lp(a) clearance rather than an increase 
in Lp(a) production, consistent with the notion that the kidney degrades 
Lp(a). More studies are needed to prove the biological relevance. 
Kidney International (2007) 71, 961–962. doi:10.1038/sj.ki.5002240
Lipoprotein(a) (Lp(a)) consists of a low-
density lipoprotein (LDL)-like particle 
containing one molecule of apolipopro-
tein B-100 (apoB-100) covalently linked 
by a sulfh ydryl bond to one molecule of 
apolipoprotein(a) (apo(a)). Th e carbohy-
drate-rich glycoprotein apo(a) is highly 
polymorphic and is formed by variable 
copies of the kringle 4 domain, one copy 
of a kringle 5 domain, and an inactive 
protease domain.
Lp(a) is almost exclusively derived from 
the liver. Frischmann and co-workers1 
(this issue) compared the in vivo turnover 
rates of both the apoB-100 component and 
the apo(a) component of Lp(a) by stable-
isotope technology in healthy controls and 
in hemodialysis patients. Th is work dem-
onstrated that the apoB-containing lipo-
proteins from which Lp(a) is assembled 
are almost exclusively a newly synthesized 
pool derived from the liver in both controls 
and hemodialysis patients whereas only a 
very small percentage of Lp(a) is assem-
bled from circulating LDL. Plasma levels of 
Lp(a) are highly variable; most of the varia-
tion is attributed to diff erences in the Lp(a) 
production rate controlled by the apo(a) 
gene locus. Considerable progress has 
been made in regard to our understanding 
of Lp(a) assembly and production, but little 
is known about the sites and mechanisms 
responsible for Lp(a) clearance (Figure 1).
Th ere is now a considerable amount of 
evidence supporting the concept that the 
kidney plays a significant role in Lp(a) 
clearance. First, Lp(a) plasma concentra-
tions are elevated in patients with impaired 
renal function,2 and the degree of Lp(a) 
elevation inversely correlates with the 
glomerular fi ltration rate.3 Interestingly, 
the majority of studies have suggested that 
the high-molecular weight forms of Lp(a) 
are selectively elevated in patients with 
impaired renal function. Second, after 
kidney transplantation in patients with 
impaired renal function, Lp(a) concentra-
tions generally decrease.4 Th ird, Kronen-
berg and co-workers5 reported that Lp(a) 
levels in the renal vein are lower than those 
in the ascending aorta, suggesting that 
Lp(a) is removed in the renal circulation. 
Fourth, Reblin and co-workers6 showed, in 
a heterologous rat model, that when Lp(a) 
is injected in rats, Lp(a) accumulates in the 
kidney tubules and apo(a) fragments are 
excreted in the urine. Fift h, patients with 
impaired renal function have decreased 
urinary apo(a) excretion.2 Frischmann and 
co-workers1 have extended these observa-
tions that support a role of the kidney in 
the clearance of Lp(a) by demonstrating 
that hemodialysis patients with impaired 
renal function have a decrease in Lp(a) 
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clearance but do not exhibit an increase in 
Lp(a) production. Th ese fi ndings also indi-
cate that Lp(a) in hemodialysis patients 
has a longer retention time than that in 
controls with healthy kidney function. 
However, none of the above fi ndings rule 
out the possibility that impaired kidney 
function infl uences Lp(a) degradation at 
sites other than the kidney.
Not all studies have concluded that the 
kidney plays a signifi cant role in plasma 
clearance of Lp(a). Cain and co-workers,7 
using a heterologous mouse model to 
study Lp(a) catabolism, injected isolated 
Lp(a) radiolabeled with tyramine cellobi-
ose into wild-type, LDL receptor-defi cient, 
and apoE-defi cient mice. Th ese carefully 
performed studies demonstrated that the 
liver is the major organ accounting for the 
clearance of human-derived Lp(a) in mice, 
whereas the kidney accounted for only 
about 1% of the tissue uptake of Lp(a). 
Furthermore, in this model, neither the 
LDL receptor nor apoE played a signifi -
cant role in Lp(a) clearance; apo(a) itself 
acted as a potent inhibitor of Lp(a) clear-
ance.7 Ye and co-workers8 obtained simi-
lar results upon injecting rats with Lp(a) 
labeled with a non-hydrolyzable ether. 
Unfortunately, the fi ndings obtained with 
the use of heterologous models to evalu-
ate the role of specifi c tissues and receptors 
in Lp(a) clearance may not apply to Lp(a) 
clearance in humans, particularly as nei-
ther the mouse nor the rat produces Lp(a). 
Th e use of animals that synthesize Lp(a), 
such as the rhesus monkey or baboon, 
would be more suitable for exploring the 
mechanisms of Lp(a) catabolism.
A variety of cellular receptors have been 
suggested to play a role in Lp(a) clearance, 
including the LDL receptor, the very-low-
density lipoprotein (VLDL) receptor, the 
LDL receptor-related protein (LRP), plas-
minogen receptors, and megalin gp330 
(Figure 1). Several in vivo studies in 
humans, however, suggest that neither the 
LDL receptor nor LRP plays a signifi cant 
role in Lp(a) removal. A combination of in 
vitro and in vivo clearance studies in mice 
suggests that the VLDL receptor could play 
a role in Lp(a) removal in non-hepatic tis-
sues.9 As the VLDL receptor is expressed 
in the human kidney, it could contribute 
to the kidney’s role in Lp(a) removal. In 
vitro studies using a mouse embryonic 
yolk sac cell line have suggested that mega-
lin gp330 is involved in Lp(a) uptake and 
degradation.10 As megalin gp330 is highly 
expressed in kidney proximal tubule cells, 
additional analysis of the potential role of 
this receptor in the removal of Lp(a) by the 
kidney is warranted.
Although a considerable amount of cir-
cumstantial evidence, including the cur-
rent work of Frischmann and co-workers,1 
supports a signifi cant role of the kidney in 
Lp(a) clearance, direct evidence for renal 
uptake in humans is still lacking. Hope-
fully, the studies reviewed in this Com-
mentary will encourage others to further 
explore the putative role of the kidney in 
Lp(a) catabolism.
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Figure 1 | Schematic representation of proposed pathways for lipoprotein(a) catabolism. 
Circulating lipoprotein(a) (Lp(a)) is derived from apolipoprotein(a) that is synthesized and secreted 
by the liver (black arrows); proposed routes of Lp(a) removal from the circulation are shown by red 
arrows. Although the pathways of Lp(a) catabolism in vivo are unclear, the liver seems to play a major 
role in this process (solid red arrow). Additionally, the kidney (dashed red arrow) appears to contribute 
to Lp(a) clearance, as is evidenced, for example, by the decreased fractional catabolic rate observed in 
hemodialysis patients with compromised renal function (see Frischmann et al.,1 this issue). Peripheral 
tissues (dashed red arrow) also may contribute to Lp(a) removal from the circulation. For all routes of 
catabolism, possible clearance receptors are listed, although their respective contributions to Lp(a) 
clearance in vivo remain to be determined. apoB-100, apolipoprotein B-100.
